Home

overview

Significant disparities in the healthcare system limit access to specialized care, advanced diagnostics, and novel treatments for hypertrophic cardiomyopathy (HCM), particularly affecting patients in rural, underserved, and minority communities. Barriers such as inadequate referral pathways, insurance coverage issues, and socioeconomic factors delay diagnosis and hinder access to advanced and disease-modifying therapies. Additionally, the underrepresentation of minority populations in HCM clinical trials compromises the applicability of research findings to diverse patient groups, further exacerbating inequities in care.

Join our esteemed panel of experts to learn about HCM in underserved and minority populations focusing on key diagnostic challenges, access to medical therapy and emerging treatments, and how to address systemic inequities through shared decision making to improve outcomes and quality of life for all patients with HCM.

This event is not part of ACC.25 and is not sponsored or endorsed by the American College of Cardiology. This event does not qualify for continuing medical education (CME), continuing nursing education (CNE) or continuing education (CE) credit.

faculty

CHAIRPERSON

Carolyn Y. Ho, MD

Professor of Medicine, Harvard Medical School

Medical Director, Cardiovascular Genetics Center

Brigham and Women’s Hospital

Boston, Massachusetts

PANELIST

Sharon Cresci, MD

Professor of Medicine and Genetics

Associate director, WUMS/BJH Hypertrophic Cardiomyopathy Center

Director, IMPACT (Initiative for Mentoring, Promoting Networking and Advocacy for Cardiology Trainees)

Washington University

Cardiovascular Division

St Louis, Missouri

PANELIST

Nosheen Reza, MD, MS, FACC, FHFSA

Assistant Professor of Medicine

Penn Center for Inherited Cardiovascular Disease

Section of Advanced Heart Failure, Transplantation, and Mechanical Support

University of Pennsylvania

Philadelphia, Pennsylvania

AGENDA

Introduction

Recognizing Symptoms and Diagnosing HCM

Exploring Diagnostic Tools and Overcoming Barriers

Overview of Therapeutic Strategies for HCM: Current and Emerging Approaches

Case Challenges: Navigating Therapeutic Decision-Making and Equity in HCM Treatment

Expert Panel Discussion: Best Practices for Equitable HCM Management and Integration of New Therapies

Summary and Conclusion

Q&A

TARGET AUDIENCE

This educational activity is intended for an audience of cardiologists, primary care physicians, surgeons, nurse practitioners, physician assistants, and nurses in the United States.

GOAL STATEMENT

The goal of this activity is for learners to be better able to enhance the competence and performance of cardiologists and other healthcare practitioners in identifying and managing HCM, with a particular focus on addressing diagnostic disparities, reducing barriers to equitable care, and integrating emerging therapeutic approaches, including cardiac myosin inhibitors (CMIs), into clinical practice to optimize patient outcomes.

LEARNING OBJECTIVES

Upon completion of this activity, participants will: [break] [break] Have increased knowledge regarding the [break] [LIST] [ITEM]Latest data on current and emerging therapeutic options for HCM, including the role of cardiac myosin inhibition, and discuss their clinical application based on patient presentation and disease severity [/LIST] [break] Have greater competence related to [break] [LIST] [ITEM]Recognition of common and atypical presentations of HCM, particularly in underserved and minority populations, and identification of key diagnostic challenges that may contribute to delays in diagnosis  [ITEM]Application of evidence-based diagnostic strategies, including advanced imaging and genetic testing, to differentiate HCM from other cardiovascular conditions, while considering barriers that may impact access to these tools in diverse patient populations [/LIST] [break] Demonstrate greater confidence in their ability to [break] [LIST] [ITEM]Integrate strategies to shared decision-making that take into account cultural, socioeconomic, and language barriers to ensure that all patients have access to guideline-directed medical therapy and emerging treatment for HCM [ITEM]Develop a multidisciplinary approach to managing HCM [/LIST]

A Patient Journey to Achieve Equitable Care IME